Dr. Antonio Llombart

Head of Medical Oncology department at Hopsital Arnau Vilanova and profesor of oncology at UCV in Valencia. Trained in Breast Cancer Research in France and US. LArge experience and KOL in endocrine therapy and targeted agents in Breast Cancer.


Day 2 30 SEP

Treatment options after CDK4/6 inhibitors in advanced breast cancer in 2022: Hormonal/chemotherapy/ADC


Day 2 30 SEP

Adjuvant therapy in TNBC with residual disease post NAC: capecitabine, pembrolizumab, olaparib or in combination